Loading patent…
AssigneesOmeros Corporation, University of Leicester
InventorsGregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
Estimating the term…
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
A method of inhibiting MASP-2 dependent complement activation in a subject at risk for developing or suffering from acute radiation syndrome comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to reduce one or more detrimental effects of exposure to ionizing radiation selected from the group consisting of nausea, vomiting, diarrhea, skin damage, hair loss, fatigue, fever, seizures and coma.
Dependencies are inferred from the claim text.